T. Riccobene

发表

Modeling activation and desensitization of G-protein coupled receptors provides insight into ligand efficacy.

J. Linderman, T. Riccobene, G. Omann, 1999, Journal of theoretical biology.

HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo

M. Fiscella, J. Carrell, P. Kanakaraj, 2005, British Journal of Cancer.

Dose Selection and Validation for Ceftazidime-Avibactam in Adults with Complicated Intra-abdominal Infections, Complicated Urinary Tract Infections, and Nosocomial Pneumonia

T. Riccobene, Jianguo Li, I. Critchley, 2019, Antimicrobial Agents and Chemotherapy.

Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa

T. Riccobene, I. Critchley, Shampa Das, 2018, Antimicrobial Agents and Chemotherapy.

Ceftaroline fosamil for the treatment of acute bacterial skin and skin structure infections

T. Riccobene, G. Udeani, A. Jandourek, 2014, Expert review of clinical pharmacology.

Antimicrobial Activity of Ceftazidime-Avibactam and Comparators against Pathogens Harboring OXA-48 and AmpC Alone or in Combination with Other β-Lactamases Collected from Phase 3 Clinical Trials and an International Surveillance Program

T. Riccobene, G. Stone, W.-J. Chang, 2022, Antimicrobial agents and chemotherapy.

Ceftaroline Fosamil for Treatment of Pediatric Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia

T. Riccobene, G. Stone, T. Carrothers, 2021, Pediatric Drugs.

Pharmacokinetic and Pharmacodynamic Target Attainment in Adult and Pediatric Patients Following Administration of Ceftaroline Fosamil as a 5‐Minute Infusion

T. Riccobene, P. Chan, W. Knebel, 2021, Clinical pharmacology in drug development.

Avibactam Pharmacokinetic/Pharmacodynamic Targets

T. Riccobene, I. Critchley, Shampa Das, 2018, Antimicrobial Agents and Chemotherapy.

Population PK Modeling and Target Attainment Simulations to Support Dosing of Ceftaroline Fosamil in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections and Community‐Acquired Bacterial Pneumonia

T. Riccobene, J. Bradley, W. Knebel, 2017, Journal of clinical pharmacology.

Ceftazidime–avibactam for the treatment of complicated urinary tract infections and complicated intra-abdominal infections

T. Riccobene, I. Critchley, Y. Mawal, 2015, Expert review of clinical pharmacology.

Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity.

T. Riccobene, I. Critchley, D. Thye, 2010, The Journal of antimicrobial chemotherapy.

Phase 2 Study of the Safety, Pharmacokinetics and Efficacy of Ceftaroline Fosamil in Neonates and Very Young Infants With Late-onset Sepsis

T. Riccobene, P. Chan, J. Bradley, 2020, The Pediatric infectious disease journal.

Penetration of Ceftaroline into the Epithelial Lining Fluid of Healthy Adult Subjects

T. Riccobene, W. Knebel, A. Jandourek, 2016, Antimicrobial Agents and Chemotherapy.

Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial

V. Fowler, T. Riccobene, N. Turner, 2022, Trials.

Population Pharmacokinetic Modeling and Probability of Pharmacodynamic Target Attainment for Ceftazidime‐Avibactam in Pediatric Patients Aged 3 Months and Older

T. Riccobene, P. Chan, L. Mcfadyen, 2021, Clinical pharmacology and therapeutics.

Pharmacokinetics, Safety, and Tolerability of Cariprazine in Pediatric Patients with Bipolar I Disorder or Schizophrenia.

T. Riccobene, A. Hankinson, W. Earley, 2022, Journal of child and adolescent psychopharmacology.

Threshold and graded response behavior in human neutrophils: effect of varying G-protein or ligand concentrations.

J. Linderman, A. Waller, T. Riccobene, 1998, Biochemistry.

Comment on: “Clinical Pharmacokinetics of Atypical Antipsychotics: An Update”

T. Riccobene, A. Periclou, I. Laszlovszky, 2019, Clinical Pharmacokinetics.

Pharmacokinetics and in vitro and in vivo anti-tumor response of an interleukin-2-human serum albumin fusion protein in mice

P. Wei, P. Kanakaraj, R. Melder, 2005, Cancer Immunology, Immunotherapy.

The Safety and Efficacy of Dalbavancin and Active Comparator in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections

M. Burroughs, T. Riccobene, T. Carrothers, 2022, The Pediatric infectious disease journal.

Interconverting receptor states at 4 °C for the neutrophil N-formyl peptide receptor

J. Linderman, T. Riccobene, G. Omann, 1996 .

Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator.

V. Roschke, D. Hilbert, R. Minter, 2003, Arthritis and rheumatism.

Rapid and specific targeting of 125I-labeled B lymphocyte stimulator to lymphoid tissues and B cell tumors in mice.

T. Riccobene, M. Stabin, R. Miceli, 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

A Single- and Multiple-Dose Study to Determine the Safety, Tolerability, and Pharmacokinetics (PK) of Ceftaroline (CPT) Administered by Intramuscular (IM) Injection to Healthy Subjects

T. Riccobene, 2008 .

AlbugraninTM, a Recombinant Human Granulocyte Colony Stimulating Factor (G-CSF) Genetically Fused to Recombinant Human Albumin Induces Prolonged Myelopoietic Effects in Mice and Monkeys

J. Carrell, T. Riccobene, W. Halpern, 2002, Pharmaceutical Research.

Ceftazidime‐Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient Subgroups

James G. Wright, Diansong Zhou, T. Riccobene, 2018, Clinical and translational science.

Single- and Multiple-Dose Study To Determine the Safety, Tolerability, and Pharmacokinetics of Ceftaroline Fosamil in Combination with Avibactam in Healthy Subjects

T. Riccobene, S. Su, Douglas R. Rank, 2013, Antimicrobial Agents and Chemotherapy.

Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Target Attainment Analyses for Dalbavancin in Pediatric Patients

T. Riccobene, L. Lindbom, T. Carrothers, 2022, The Pediatric infectious disease journal.

Pharmacokinetic-Pharmacodynamic Analyses for Efficacy of Ceftaroline Fosamil in Patients with Community-Acquired Bacterial Pneumonia

T. Riccobene, S. Bhavnani, P. Ambrose, 2013, Antimicrobial Agents and Chemotherapy.

Randomized Trial of Ceftazidime-Avibactam vs Meropenem for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (REPROVE): Analyses per US FDA–Specified End Points

A. Torres, T. Riccobene, H. Lakkis, 2019, Open forum infectious diseases.

Antimicrobial Activity of Ceftazidime-Avibactam Against Contemporary Pathogens From Urinary Tract Infections and Intra-abdominal Infections Collected From US Children During the 2016-2019 INFORM Surveillance Program.

T. Riccobene, D. Debabov, Lynn-Yao Lin, 2020, The Pediatric infectious disease journal.

Considerations in the Selection of Renal Dosage Adjustments for Patients with Serious Infections and Lessons Learned from the Development of Ceftazidime-Avibactam

T. Riccobene, Jianguo Li, Shampa Das, 2020, Antimicrobial Agents and Chemotherapy.

Population Pharmacokinetic Modeling for Ceftazidime‐Avibactam Renal Dose Adjustments in Pediatric Patients 3 months and Older

T. Riccobene, E. Winter, L. Mcfadyen, 2022, Clinical pharmacology and therapeutics.

A series of pharmacokinetic studies of ceftaroline fosamil in select populations: Normal subjects, healthy elderly subjects, and subjects with renal impairment or end‐stage renal disease requiring hemodialysis

T. Riccobene, Douglas R. Rank, Abhijeet S. Jakate, 2014, Journal of clinical pharmacology.

Pharmacologic and pharmacokinetic profile of repifermin (KGF-2) in monkeys and comparative pharmacokinetics in humans

V. Roschke, D. Odenheimer, T. Riccobene, 2002, AAPS PharmSci.

Pharmacokinetics and immunological effects of exogenously administered recombinant human B lymphocyte stimulator (BLyS) in mice.

Y. Li, J. Carrell, S. Sosnovtseva, 2001, The Journal of pharmacology and experimental therapeutics.

Pharmacokinetic-Pharmacodynamic Analysis for Efficacy of Ceftaroline Fosamil in Patients with Acute Bacterial Skin and Skin Structure Infections

G. Drusano, T. Riccobene, S. Bhavnani, 2014, Antimicrobial Agents and Chemotherapy.

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Evaluate In Vitro Susceptibility Test Interpretive Criteria for Ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae

T. Riccobene, S. Bhavnani, P. Ambrose, 2013, Antimicrobial Agents and Chemotherapy.

Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community‐acquired bacterial pneumonia

T. Riccobene, S. Bhavnani, P. Ambrose, 2013, Journal of clinical pharmacology.

Phase 3, Randomized, Double-blind Noninferiority (NI) Study of Ceftazidime–Avibactam (CAZ-AVI) vs. Meropenem (MER) in the Treatment of Patients with Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP): Analyses of the REPROVE Study per US FDA Endpoints

A. Torres, T. Riccobene, H. Lakkis, 2017 .

Analysis of G-protein coupled receptor signaling: The relationship between signaling parameters and cellular responses.

T. Riccobene, 1999 .

Avibactam Pharmacokinetic/Pharmacodynamic Targets

T. Riccobene, I. Critchley, Shampa Das, 2018, Antimicrobial Agents and Chemotherapy.